Teprotumumab reduces proptosis in patients with non-inflammatory TED

Teprotumumab, a human monoclonal anti-IGF-1R blocking antibody, reduced proptosis in a series of patients with non-inflammatory thyroid eye disease (TED), according to a study.

Four patients with non-inflammatory TED were treated with a complete course (8 infusions) of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for subsequent infusions every 3 weeks).

After treatment, there was a mean (SD) reduction in proptosis of 2.6 mm (1.2).

IGF-1Rα and IGF-1Rβ expression was evaluated on orbital tissue from patients with inflammatory TED (n = 5), non-inflammatory TED (n = 5), and healthy controls (n = 5). Compared to controls, IGF-1Rα and IGF-1Rβ expression was significantly greater in the tissue of patients with inflammatory TED and non-inflammatory TED.

Reference

Ugradar S, Shi L, Wang Y, et al. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye (Lond). 2020; DOI: 10.1038/s41433-020-01297-w. Epub ahead of print. PMID: 33221815.